Yahoo
Morningstar

Morningstar

•

Oct 30, 2026

Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals Earnings: Strong Growth and Pipeline Progress

Symbols

REGN

Sector(s)

Healthcare

Rating

Current Price

927.89

Fair Value

Economic Moat

Stewardship

Summary

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Upgrade
Mobilize your Website
View Site in Mobile | Classic
Share by: